ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancerBusiness Wire • 12/15/25
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025Accesswire • 12/08/25
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailingProactive Investors • 12/08/25
Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer EngagementBusiness Wire • 12/04/25
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASHBusiness Wire • 12/04/25
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled HypertensionZacks Investment Research • 12/03/25
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertensionBusiness Wire • 12/02/25
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companiesCNBC • 11/26/25
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership GrowsBenzinga • 11/24/25
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in OncologyPRNewsWire • 11/24/25
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growthBusiness Wire • 11/21/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetesReuters • 11/14/25
AstraZeneca leans on its pipeline as $80bn revenue target comes into viewProactive Investors • 11/13/25